Explore

Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials

Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials

Verastem Oncology Reports Q2 2026 Financial Results and Advances Clinical Trials

Eli Lilly Offers Limited Access to Experimental Weight Loss Drug Retatrutide for Compassionate Use

Eli Lilly Offers Limited Access to Experimental Weight Loss Drug Retatrutide for Compassionate Use

Eli Lilly Offers Limited Access to Experimental Weight Loss Drug Retatrutide for Compassionate Use

Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide

Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide

Eli Lilly Expands Access to Experimental Obesity Drug Retatrutide

Eli Lilly's Retatrutide Offers Promising Weight Loss Results Ahead of FDA Approval

Eli Lilly's Retatrutide Offers Promising Weight Loss Results Ahead of FDA Approval

Eli Lilly's Retatrutide Offers Promising Weight Loss Results Ahead of FDA Approval

Eli Lilly Increases 2026 Revenue Forecast Following Strong Q2 Performance

Eli Lilly Increases 2026 Revenue Forecast Following Strong Q2 Performance

Eli Lilly Increases 2026 Revenue Forecast Following Strong Q2 Performance

Eli Lilly Reports Strong Q2 2026 Financial Results, Raises Full-Year Guidance

Eli Lilly Reports Strong Q2 2026 Financial Results, Raises Full-Year Guidance

Eli Lilly Reports Strong Q2 2026 Financial Results, Raises Full-Year Guidance

Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio

Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio

Eli Lilly Reports 48% Revenue Surge in Q2 2026 Driven by Incretin Portfolio

Eli Lilly Exceeds Q2 2026 Earnings Expectations with Strong Drug Sales

Eli Lilly Exceeds Q2 2026 Earnings Expectations with Strong Drug Sales

Eli Lilly Exceeds Q2 2026 Earnings Expectations with Strong Drug Sales

Eli Lilly Increases Price Target Following Strong GLP-1 Drug Sales

Eli Lilly Increases Price Target Following Strong GLP-1 Drug Sales

Eli Lilly Increases Price Target Following Strong GLP-1 Drug Sales

Eli Lilly's Q2 Earnings Surpass Expectations, Driven by GLP-1 Drugs

Eli Lilly's Q2 Earnings Surpass Expectations, Driven by GLP-1 Drugs

Eli Lilly's Q2 Earnings Surpass Expectations, Driven by GLP-1 Drugs

Eli Lilly Reports 48% Revenue Growth in Q2 2026, Raises Full-Year Guidance

Eli Lilly Reports 48% Revenue Growth in Q2 2026, Raises Full-Year Guidance

Eli Lilly Reports 48% Revenue Growth in Q2 2026, Raises Full-Year Guidance

Eli Lilly Increases Revenue Forecast Amid Strong Sales of New Medications

Eli Lilly Increases Revenue Forecast Amid Strong Sales of New Medications

Eli Lilly Increases Revenue Forecast Amid Strong Sales of New Medications